📰 Patrick Burnett News
Page 2 - Patrick Burnett News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patrick Burnett. Real-time updates on events, politics, business and more.
December 18, 2023
Arcutis Biotherapeutics has received US FDA approval for NDA for ZORYVE topical foam, 0.3%, to treat seborrheic dermatitis
December 16, 2023
The approval of the once-daily, steroid free foam marks the first approval of a drug by the FDA for the skin condition.
December 15, 2023
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
November 14, 2023
Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval for a drug.
November 6, 2023
Westlake Village-based immune-dermatology company Arcutis Biotherapeutics Inc. has received federal approval for a drug.
November 5, 2023
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript November 3, 2023 Arcutis Biotherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.9. Operator: Good day, and welcome to the Arcutis Biotherapeutics Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like […]
October 6, 2023
WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S.
October 6, 2023
Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.
October 6, 2023
The FDA has approved Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children ages 6 to 11 years.
September 19, 2023
A supplemental New Drug Application will be submitted for roflumilast cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.